IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG (IMPACT-CABG)

• ClinicalTrials.gov Identifier: NCT01033617
• Recruitment Status: Completed
• First Posted: December 16, 2009
• Last Update Posted: October 18, 2017
• Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
• Collaborators: Miltenyi Biotec, Inc.; Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Maisonneuve-Rosemont Hospital
• Information provided by (Responsible Party): Centre hospitalier de l'Université de Montréal (CHUM)

Study Description

Brief Summary:

Following myocardial infarct, cellular therapy is a potential approach to repopulate the injured myocardium, to treat heart failure and restore cardiac function. The purpose of this study is to assess the safety, feasibility and efficacy of intramyocardial delivery of selected autologous CD133+ bone marrow stem cells at time of coronary artery bypass grafting in patients with chronic ischemic cardiomyopathy.

Condition or disease	Intervention/treatment	Phase
Myocardial Infarct; Heart Failure	Procedure: Injection of stem cells at time of coronary artery bypass grafting	Not Applicable

Detailed Description:

CD133+ are well-characterized distinct early progenitor group of stem cells that possess high engraftment, pluripotent and angiogenic capacity and proved to be valuable for cardiac repair by promoting neovascularization, inhibition of apoptosis and cardiomyogenesis.

Our proposed research protocol involves patients with chronic ischemic heart disease and left ventricular dysfunction undergoing coronary artery bypass grafting (CABG). In this phase II clinical trial, prospective, randomized, 2 arm, double-blind, placebo-controlled study, we will assess the safety, feasibility and functional effect of intra-myocardial injection of highly selected autologous CD133+ bone marrow stem cells to placebo.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Stem cell or placebo
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: double blind
• Primary Purpose: Treatment
• Official Title: The IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG With Left Ventricular Dysfunction: the IMPACT-CABG Study
• Study Start Date: December 2009
• Actual Primary Completion Date: December 2014
• Actual Study Completion Date: June 2016

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Saline solution with autologous plasma.	Procedure: Injection of stem cells at time of coronary artery bypass grafting; Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.; Other Name: CD133+ autologous stem cells OR placebo solution containing autologous plasma
Experimental: CD133+ stem cells; Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.	Procedure: Injection of stem cells at time of coronary artery bypass grafting; Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.; Other Name: CD133+ autologous stem cells OR placebo solution containing autologous plasma

Outcome Measures

Primary Outcome Measures :

1. Freedom from Major Adverse Cardiac Event: cardiac death, myocardial infarct, repeat coronary bypass grafting or percutaneous intervention of bypassed artery. [ Time Frame: 6 months ]
2. Freedom from major arrhythmia: sustained ventricular tachycardia or survived sudden death. [ Time Frame: 6 months ]

Secondary Outcome Measures :

1. Regional myocardial perfusion and function assessed by magnetic resonance scans. [ Time Frame: 6 months ]
2. Device performance end point: Feasibility to produce from 100ml of bone marrow aspiration a final cell product that contains a target CD133+ cells higher than 0.5 million with a purity superior to 30% and a recovery superior to 10%. [ Time Frame: Baseline ]
3. On symptom severity and quality of life after CABG surgery. [ Time Frame: 6 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age ≥18 years, and ≤75 years.
• Patients with severe chronic ischemic cardiomyopathy manifested by Canadian Cardiovascular Society (CCS) class II or greater angina, and/or New York Heart Association (NYHA) class II or greater, AND who have undergone diagnostic coronary angiography demonstrating ≥70% diameter narrowing of at least 2 major coronary arteries or branches or ≥50% diameter narrowing of the left main coronary artery.
• A significant left ventricular systolic dysfunction evaluated by echocardiography or LV angiography (LV ejection fraction ≤45% but ≥25%) due to prior myocardial infarction. This area of left ventricular dysfunction should be akinetic or severely hypokinetic, not dyskinetic or aneurismal, when assessed by echocardiography or LV angiogram. This territory should be irrigated by one or a branch of the three major vascular territories (i.e. right coronary artery, left circumflex, or left anterior descending artery distribution) that will be bypassed during the surgical procedure.
• No contraindications or exclusions (see below).
• Willingness to participate and ability to provide informed consent.

Exclusion Criteria:

• Contraindications to magnetic resonance imaging including presence of an implantable cardiac defibrillator (ICD) or permanent pacemaker (PPM), or cases in which it is anticipated that an ICD or PPM will be implanted prior to the 6 month follow-up (thus precluding performance of follow-up MR scans), claustrophobia.
• Lack of ischemic symptoms (angina) prior to referral for CABG (i.e., patients with only 'silent' ischemia will be excluded).
• Need for urgent or emergent revascularization.
• Need for concomitant surgical procedure at the time of CABG (e.g. valve repair or replacement, aneurysm resection, etc.).
• Hemodynamically unstable patients, as defined by heart rate ≤40/min or ≥100/min, and/or systolic blood pressure <90 mmHg or ≥200 mmHg, and/or ongoing need for intravenous inotropic or vasopressor medications.
• Patients with confirmed myocardial infarction within 14 days, and/or rising cardiac biomarker proteins (i.e. troponin), and/or worsening ECG changes.
• Prior CABG surgery.
• Stroke within 3 months prior to planned CABG.
• Immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)
• Severe chronic renal insufficiency (serum creatinine ≥ 200 mmol/dl or need for dialysis), liver disease, (diagnosis of cirrhosis, chronic hepatitis, or elevation of serum transaminases ≥3 times the upper limit of normal), cerebrovascular disease requiring concomitant carotid endarterectomy, peripheral arterial disease (claudication as the primary factor limiting activity), active non-dermatological malignancy requiring on-going treatment, or any other condition that would place the patient at increased risk for complications in the judgment of the attending cardiologist or cardiac surgeon
• Contra-indication for bone marrow aspiration (Thrombocytopenia <50.000 mm3, INR >2.0, use of antiplatelet agents other than aspirin).
• Hemoglobin less than 10g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3
• Active infection, with a temperature greater than 37.5°C within 48 hrs prior to surgery and an unexplained white blood cell count in excess of 10,000/mm3
• Myelodysplastic syndrome (MDS)
• Significant cognitive impairment
• Any condition associated with a life expectancy of less than 6 months
• Patients known allergic reaction or contraindication to any of the component of the CD133+ enriched cells
• Participation in other studies
• History of severe ventricular tachy-arrythmias
• Positive laboratory test results for syphilis, HIV, HBC, HCV, HTLV1 and HTLV2
• Pregnant woman
• Inability or unwillingness to provide written informed consent

Contacts and Locations

Locations

Canada, Quebec

Centre de recherche du CHUM (CRCHUM)

Montreal, Quebec, Canada, H2W 1T8

Sponsors and Collaborators

Centre hospitalier de l'Université de Montréal (CHUM)

Miltenyi Biotec, Inc.

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Maisonneuve-Rosemont Hospital

Investigators

• Principal Investigator: Nicolas Noiseux, MD, MSc, FRCSC; Montreal University

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Noiseux N, Mansour S, Weisel R, Stevens LM, Der Sarkissian S, Tsang K, Crean AM, Larose E, Li SH, Wintersperger B, Vu MQ, Prieto I, Li RK, Roy DC, Yau TM. The IMPACT-CABG trial: A multicenter, randomized clinical trial of CD133+ stem cell therapy during coronary artery bypass grafting for ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2016 Dec;152(6):1582-1588.e2. doi: 10.1016/j.jtcvs.2016.07.067. Epub 2016 Aug 13.

• Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
• ClinicalTrials.gov Identifier: NCT01033617
• Other Study ID Numbers: HD08.147
• First Posted: December 16, 2009
• Last Update Posted: October 18, 2017
• Last Verified: July 2015

Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):

Stem cells; Cellular therapy; Myocardial repair

Additional relevant MeSH terms:

Myocardial Infarction; Heart Diseases; Cardiovascular Diseases; Infarction; Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Vascular Diseases